Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Massimo Zuin

Showing results (61-70 of 72) with videos related to

Pageof 8
Sort By:
Liver International : Official Journal of the International Association for the Study of the Liver|July 22, 2014
Interleukin-28B genetic variants in untreated Italian HCV-infected patients: a multicentre studyLeonardo Mottola, Giovanni Cenderello, Valeria A Piazzolla, et al.
JHEP Reports : Innovation in Hepatology|March 14, 2026
Evaluation of novel assays of non-ceruloplasmin copper to monitor chelation treatment in patients with Wilson disease: Monitoring chelation treatment in Wilson diseasePeter Ott, Thomas Sandahl, Aftab Ala, et al.
The Lancet. Gastroenterology & Hepatology|October 2, 2022
Trientine tetrahydrochloride versus penicillamine for maintenance therapy in Wilson disease (CHELATE): a randomised, open-label, non-inferiority, phase 3 trialMichael L Schilsky, Anna Czlonkowska, Massimo Zuin, et al.
JHEP Reports : Innovation in Hepatology|August 14, 2024
Non-ceruloplasmin copper and urinary copper in clinically stable Wilson disease: Alignment with recommended targetsPeter Ott, Thomas Sandahl, Aftab Ala, et al.
Frontiers in Public Health|January 25, 2021
The Many Faces of Covid-19 at a Glance: A University Hospital Multidisciplinary Account From Milan, ItalyAlberto Priori, Alessandro Baisi, Giuseppe Banderali, et al.
Hepatology International|April 13, 2020
Advanced liver disease outcomes after hepatitis C eradication by human immunodeficiency virus infection in PITER cohortMaria Giovanna Quaranta, Luigina Ferrigno, Monica Monti, et al.
Hepatology (Baltimore, Md.)|July 26, 2017
Modeling cost-effectiveness and health gains of a "universal" versus "prioritized" hepatitis C virus treatment policy in a real-life cohortLoreta A Kondili, Federica Romano, Francesca Romana Rolli, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|December 10, 2019
Renal safety in 3264 HCV patients treated with DAA-based regimens: Results from a large Italian real-life studyRoberta D'Ambrosio, Luisa Pasulo, Alessia Giorgini, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|June 15, 2018
Forecasting Hepatitis C liver disease burden on real-life data. Does the hidden iceberg matter to reach the elimination goals?Loreta A Kondili, Sarah Robbins, Sarah Blach, et al.
The Lancet. Gastroenterology & Hepatology|July 19, 2018
Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response ScoreMarco Carbone, Alessandra Nardi, Steve Flack, et al.
Pageof 8

Showing results (61-70 of 72) with videos related to

Sort By:
Pageof 8
Liver International : Official Journal of the International Association for the Study of the Liver|July 22, 2014
Interleukin-28B genetic variants in untreated Italian HCV-infected patients: a multicentre studyLeonardo Mottola, Giovanni Cenderello, Valeria A Piazzolla, et al.
JHEP Reports : Innovation in Hepatology|March 14, 2026
Evaluation of novel assays of non-ceruloplasmin copper to monitor chelation treatment in patients with Wilson disease: Monitoring chelation treatment in Wilson diseasePeter Ott, Thomas Sandahl, Aftab Ala, et al.
The Lancet. Gastroenterology & Hepatology|October 2, 2022
Trientine tetrahydrochloride versus penicillamine for maintenance therapy in Wilson disease (CHELATE): a randomised, open-label, non-inferiority, phase 3 trialMichael L Schilsky, Anna Czlonkowska, Massimo Zuin, et al.
JHEP Reports : Innovation in Hepatology|August 14, 2024
Non-ceruloplasmin copper and urinary copper in clinically stable Wilson disease: Alignment with recommended targetsPeter Ott, Thomas Sandahl, Aftab Ala, et al.
Frontiers in Public Health|January 25, 2021
The Many Faces of Covid-19 at a Glance: A University Hospital Multidisciplinary Account From Milan, ItalyAlberto Priori, Alessandro Baisi, Giuseppe Banderali, et al.
Hepatology International|April 13, 2020
Advanced liver disease outcomes after hepatitis C eradication by human immunodeficiency virus infection in PITER cohortMaria Giovanna Quaranta, Luigina Ferrigno, Monica Monti, et al.
Hepatology (Baltimore, Md.)|July 26, 2017
Modeling cost-effectiveness and health gains of a "universal" versus "prioritized" hepatitis C virus treatment policy in a real-life cohortLoreta A Kondili, Federica Romano, Francesca Romana Rolli, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|December 10, 2019
Renal safety in 3264 HCV patients treated with DAA-based regimens: Results from a large Italian real-life studyRoberta D'Ambrosio, Luisa Pasulo, Alessia Giorgini, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|June 15, 2018
Forecasting Hepatitis C liver disease burden on real-life data. Does the hidden iceberg matter to reach the elimination goals?Loreta A Kondili, Sarah Robbins, Sarah Blach, et al.
The Lancet. Gastroenterology & Hepatology|July 19, 2018
Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response ScoreMarco Carbone, Alessandra Nardi, Steve Flack, et al.
Pageof 8